Analyst Ratings For NASDAQ:JAZZ – Jazz Pharmaceuticals (NASDAQ:JAZZ)
Today, BMO Capital Markets raised its price target on NASDAQ:JAZZ – Jazz Pharmaceuticals (NASDAQ:JAZZ) to per share.
Some recent analyst ratings include
- 4/30/2018-Cantor Fitzgerald Reiterated Rating of Buy.
- 3/23/2018-HC Wainwright Reiterated Rating of Neutral.
- 3/19/2018-Morgan Stanley Upgrade from a “Equal Weight ➝ Overweight” rating to a “” rating.
- 3/1/2018-Piper Jaffray Reiterated Rating of Buy.
Recent Insider Trading Activity For NASDAQ:JAZZ – Jazz Pharmaceuticals (NASDAQ:JAZZ)
NASDAQ:JAZZ – Jazz Pharmaceuticals (NASDAQ:JAZZ) has insider ownership of 4.30% and institutional ownership of 91.01%.
- On 5/1/2018 Bruce C Cozadd, CEO, sold 1,000 with an average share price of $151.57 per share and the total transaction amounting to $151,570.00.
- On 4/16/2018 Matthew P Young, CFO, sold 700 with an average share price of $156.01 per share and the total transaction amounting to $109,207.00.
- On 4/13/2018 Michael Patrick Miller, EVP, sold 200 with an average share price of $157.49 per share and the total transaction amounting to $31,498.00.
- On 4/10/2018 Karen J Wilson, SVP, sold 3,899 with an average share price of $155.00 per share and the total transaction amounting to $604,345.00.
- On 4/2/2018 Bruce C Cozadd, CEO, sold 1,000 with an average share price of $150.01 per share and the total transaction amounting to $150,010.00.
- On 3/15/2018 Matthew P Young, CFO, sold 700 with an average share price of $151.22 per share and the total transaction amounting to $105,854.00.
- On 3/14/2018 Michael Patrick Miller, EVP, sold 200 with an average share price of $151.12 per share and the total transaction amounting to $30,224.00.
Recent Trading Activity for NASDAQ:JAZZ – Jazz Pharmaceuticals (NASDAQ:JAZZ)
Shares of NASDAQ:JAZZ – Jazz Pharmaceuticals closed the previous trading session at 158.40 up +10.84 7.35% with 150.9199981689453 shares trading hands.